File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
  • Basic View
  • Metadata View
  • XML View
TitleEZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
 
AuthorsCai, MY2
Tong, ZT2
Zheng, F2
Liao, YJ2
Wang, Y2
Rao, HL2
Chen, YC3
Wu, QL2
Liu, YH1
Guan, XY2
Lin, MC2 3
Zeng, YX2
Kung, HF2 3
Xie, D2
 
Issue Date2011
 
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
CitationGut, 2011, v. 60 n. 7, p. 967-976 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2010.231993
 
AbstractBackground and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.
 
ISSN0017-5749
2012 Impact Factor: 10.732
2012 SCImago Journal Rankings: 3.379
 
DOIhttp://dx.doi.org/10.1136/gut.2010.231993
 
ISI Accession Number IDWOS:000291306900016
Funding AgencyGrant Number
China's 973 National Basic Research Programme2010CB529401
2010CB912803
863 High Technology Development Programme2007AA021901
Guangzhou Science and Technology Bureau Foundation2005Z1-E0131
Funding Information:

This study was supported by grants made under China's 973 National Basic Research Programme (Nos. 2010CB529401 and 2010CB912803) and 863 High Technology Development Programme (No. 2007AA021901), and by a grant from the Guangzhou Science and Technology Bureau Foundation (No. 2005Z1-E0131).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorCai, MY
 
dc.contributor.authorTong, ZT
 
dc.contributor.authorZheng, F
 
dc.contributor.authorLiao, YJ
 
dc.contributor.authorWang, Y
 
dc.contributor.authorRao, HL
 
dc.contributor.authorChen, YC
 
dc.contributor.authorWu, QL
 
dc.contributor.authorLiu, YH
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorLin, MC
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorKung, HF
 
dc.contributor.authorXie, D
 
dc.date.accessioned2011-08-26T14:22:15Z
 
dc.date.available2011-08-26T14:22:15Z
 
dc.date.issued2011
 
dc.description.abstractBackground and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationGut, 2011, v. 60 n. 7, p. 967-976 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2010.231993
 
dc.identifier.doihttp://dx.doi.org/10.1136/gut.2010.231993
 
dc.identifier.epage976
 
dc.identifier.hkuros190887
 
dc.identifier.isiWOS:000291306900016
Funding AgencyGrant Number
China's 973 National Basic Research Programme2010CB529401
2010CB912803
863 High Technology Development Programme2007AA021901
Guangzhou Science and Technology Bureau Foundation2005Z1-E0131
Funding Information:

This study was supported by grants made under China's 973 National Basic Research Programme (Nos. 2010CB529401 and 2010CB912803) and 863 High Technology Development Programme (No. 2007AA021901), and by a grant from the Guangzhou Science and Technology Bureau Foundation (No. 2005Z1-E0131).

 
dc.identifier.issn0017-5749
2012 Impact Factor: 10.732
2012 SCImago Journal Rankings: 3.379
 
dc.identifier.issue7
 
dc.identifier.pmid21330577
 
dc.identifier.scopuseid_2-s2.0-79958219307
 
dc.identifier.spage967
 
dc.identifier.urihttp://hdl.handle.net/10722/137272
 
dc.identifier.volume60
 
dc.languageeng
 
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofGut
 
dc.relation.referencesReferences in Scopus
 
dc.rightsGut. Copyright © BMJ Publishing Group.
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshCarcinoma, Hepatocellular - diagnosis - pathology
 
dc.subject.meshDNA-Binding Proteins - metabolism
 
dc.subject.meshLiver Neoplasms - diagnosis - pathology
 
dc.subject.meshTranscription Factors - metabolism
 
dc.subject.meshTumor Markers, Biological - metabolism
 
dc.titleEZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cai, MY</contributor.author>
<contributor.author>Tong, ZT</contributor.author>
<contributor.author>Zheng, F</contributor.author>
<contributor.author>Liao, YJ</contributor.author>
<contributor.author>Wang, Y</contributor.author>
<contributor.author>Rao, HL</contributor.author>
<contributor.author>Chen, YC</contributor.author>
<contributor.author>Wu, QL</contributor.author>
<contributor.author>Liu, YH</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Lin, MC</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2011-08-26T14:22:15Z</date.accessioned>
<date.available>2011-08-26T14:22:15Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Gut, 2011, v. 60 n. 7, p. 967-976</identifier.citation>
<identifier.issn>0017-5749</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137272</identifier.uri>
<description.abstract>Background and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.</description.abstract>
<language>eng</language>
<publisher>BMJ Publishing Group. The Journal&apos;s web site is located at http://gut.bmjjournals.com/</publisher>
<relation.ispartof>Gut</relation.ispartof>
<rights>Gut. Copyright &#169; BMJ Publishing Group.</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Carcinoma, Hepatocellular - diagnosis - pathology</subject.mesh>
<subject.mesh>DNA-Binding Proteins - metabolism</subject.mesh>
<subject.mesh>Liver Neoplasms - diagnosis - pathology</subject.mesh>
<subject.mesh>Transcription Factors - metabolism</subject.mesh>
<subject.mesh>Tumor Markers, Biological - metabolism</subject.mesh>
<title>EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1136/gut.2010.231993</identifier.doi>
<identifier.pmid>21330577</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79958219307</identifier.scopus>
<identifier.hkuros>190887</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79958219307&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>60</identifier.volume>
<identifier.issue>7</identifier.issue>
<identifier.spage>967</identifier.spage>
<identifier.epage>976</identifier.epage>
<identifier.isi>WOS:000291306900016</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/137272/1/content.pdf</bitstream.url>
</item>
Author Affiliations
  1. Guangdong Provincial People's Hospital
  2. Sun Yat-Sen University
  3. Chinese University of Hong Kong